Mitochondrial-Targeted Peptides (MTP)

Mitochondrial-targeted peptides are short synthetic sequences, typically 2 to 8 amino acids, designed to localize to mitochondria and protect against oxidative damage and organelle dysfunction. Representative compounds include SS-31 (elamipretide), a tetrapeptide that associates with cardiolipin in the inner mitochondrial membrane to reduce reactive oxygen species and improve electron transport chain efficiency.

These peptides aim to address mitochondrial dysfunction implicated in aging, heart failure, neurodegenerative disease, and ischemia-reperfusion injury. The longevity application is based on the mitochondrial theory of aging and evidence that mitochondrial protection extends lifespan in model organisms..

Mitochondrial-Targeted Peptides (MTP) is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.